Enveric inks $62M licensing deal for psilocin prodrug
The biotech will concentrate on its “trip-free” compound, especially following recent FDA concerns on psychedelic trial designs.
The post Enveric inks $62M licensing deal for psilocin prodrug appeared first on Green Market Report.
